JOHNS HOPKINS UNIVERSITY

🇳🇦Namibia

Country: 🇳🇦Namibia

Ownership: -

Established: 1876-01-01

Employees: 19.4K

Market Cap: -

Website: https://www.jhu.edu/

Clinical Trials

e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English

Not Applicable

Completed

Conditions: Breast Cancer
Cervical Cancer

Interventions: Behavioral: CHEC-uP
Behavioral: e-CHEC-uP

First Posted Date: 2018-10-31

Last Posted Date: 2020-08-19

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 40

Registration Number: NCT03726619

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Post-extubation Assessment of Laryngeal Symptoms and Severity

Completed

Conditions: Intubation, Intratracheal
Complication of Ventilation Therapy
Critical Illness
Mechanical Ventilation Complication

First Posted Date: 2018-10-31

Last Posted Date: 2023-07-06

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 365

Registration Number: NCT03726086

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Single Dose Truvada Study

Phase 1

Completed

Conditions: Medication Adherence
HIV Prevention

Interventions: Drug: Tenofovir

First Posted Date: 2018-10-25

Last Posted Date: 2020-07-16

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 44

Registration Number: NCT03719053

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Analysis of Crushed and Whole Tablet Genvoya

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Genvoya Crushed Dose
Drug: Genvoya Oral dose

First Posted Date: 2018-10-24

Last Posted Date: 2023-01-31

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 12

Registration Number: NCT03717129

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Bimatoprost as a Treatment for Graves' Orbitopathy

Early Phase 1

Recruiting

Conditions: Graves Ophthalmopathy

Interventions: Drug: Bimatoprost Ophthalmic

First Posted Date: 2018-10-17

Last Posted Date: 2024-07-18

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 3

Registration Number: NCT03708627

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Effect of Abaloparatide on Lumbar Disc Degeneration

Phase 2

Withdrawn

Conditions: Degeneration Disc Intervertebral

Interventions: Drug: Placebo
Drug: Abaloparatide

First Posted Date: 2018-10-17

Last Posted Date: 2021-04-12

Lead Sponsor: Johns Hopkins University

Registration Number: NCT03708926

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

mHealth Physical Activity Trial for Older HIV-infected Adults (mFIT)

Not Applicable

Completed

Conditions: HIV

Interventions: Other: Physical Activity Counseling
Other: Digital Activity Tracker
Other: Smart Text Messaging

First Posted Date: 2018-10-17

Last Posted Date: 2022-07-05

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 20

Registration Number: NCT03708640

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Bivalirudin vs Heparin in ECMO Patients

Phase 1

Withdrawn

Conditions: Extracorporeal Membrane Oxygenation Complication

Interventions: Drug: Bivalirudin Injection [Angiomax]
Drug: Heparin Sodium

First Posted Date: 2018-10-16

Last Posted Date: 2021-01-19

Lead Sponsor: Johns Hopkins University

Registration Number: NCT03707418

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Long Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy

Active, not recruiting

Conditions: Obesity
GERD

Interventions: Procedure: Surgery
Procedure: Endoscopy

First Posted Date: 2018-10-15

Last Posted Date: 2025-03-10

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 250

Registration Number: NCT03705416

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Northwell Health, New Hyde Park, New York, United States
🇺🇸
Weill Cornell, New York, New York, United States

and more 3 locations

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Terminated

Conditions: Neovascular Age-related Macular Degeneration
Submacular Hemorrhage
Wet Macular Degeneration

Interventions: Drug: Anti-VEGF
Other: Hemorrhage displacement + Anti-VEGF

First Posted Date: 2018-10-09

Last Posted Date: 2020-02-19

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 1

Registration Number: NCT03699618

Locations: 🇺🇸
Wilmer Eye Institute, Johns Hopkins, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy